Evotec wins $2.9M Gates Foundation grant for fetal safety
Alpha Vantage · Pluang · · AI-summarised by FinFlash
Evotec SE has received a $2.9 million grant from the Gates Foundation, extending its project by three years to identify fetal development risks in new drug candidates. The platform uses human stem cell-based methods and large-scale screening to deliver early safety data, reducing late-stage drug failures and reliance on animal testing.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.